AstraZeneca Aktie News

The next earnings season for European pharmaceuticals is shaping up as a test of discipline rather than momentum, with UK stocks firmly in the spotlight. That is the message from Deutsche Bank, which says the sector's strong start to the year has already pulled forward some optimism.

Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate R&D, betting on new modeling tools and automated labs to unlock efficiency gains across their pipeline.

AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.

BOSTON--(BUSINESS WIRE)-- #AstraZeneca--Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale.

AstraZeneca started 2026 on a high note. On January 7, its stock reached an all-time high of $95.94. The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises.

If a recession were to hit, it's a foregone conclusion that people won't stop taking their prescriptions, and they won't cancel major medical treatments.

At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.